P102 : Effect of escitalopram on erythematotelangiectatic rosacea

Background: There is no satisfactory treatment for erythematotelangiectatic rosacea. Objectives: To investigate the effect of escitalopram for the treatment of erythematotelangiectatic rosacea Methods: Twenty four subjects (male to female: 3:20, mean age: 44.4 years) were enrolled. Exacerbating factors were analyzed with questionnaire. Escitalopram was given at a dose of 5 mg/day for 8 weeks. Evaluation was performed at baseline and at week 8 and 24. Efficacy was evaluated through severity, investigator`s global assessment (IGA), subjective satisfaction score (SSS), chromameter and skin function test. Safety was monitored through adverse effects. Results: Exacerbating factors were sunlight, stress and hot bathing. At week 8, subjects achieved a significant decrease from 44 to 30 in severity (p<0.05). Out of 23 subjects, 5 were ranked fair, 12 good and 6 excellent in IGA. In addition, 4 were ranked fair, 12 good and 7 excellent in SSS. Chromameter showed statistically significant improvement after treatment with escitalopram, from 19.26 to 17.43 (P<0.05). Skin hydration by corneometer showed a statistically significant increase from 64.91 to 73.62 (p<0.05). Mild adverse effects, such as insomnia, facial swelling and drowsiness, were reported. At week 24, subjects achieved much more improvement in severity, IGA, SSS and chromameter. Conclusion: Escitalopram may be a useful and safe treatment option for the management of erythematotelagiectatic rosacea.